RxDoctor Payments Data

Jeffrey Eckman, MD

Internal Medicine · Fairlawn, OHNPI 1760482376

Payments from drug & device makers

$10,468in general payments, 2019–2025

Across 792 payments — averaging $13.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • Pfizer$1K
  • Amgen$1K
  • AstraZeneca$919
  • Lilly USA, LLC$739
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$10,439100%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,468 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$192,134
Medicare patients
282
Services billed
3,019

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban188$220,496
JardianceEmpagliflozin64$80,230
TrulicityDulaglutide54$75,281
OzempicSemaglutide36$34,235
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$32,464
MounjaroTirzepatide19$31,177
XareltoRivaroxaban17$25,200
JanuviaSitagliptin Phosphate15$22,456
MyrbetriqMirabegron27$21,139
Tresiba Flextouch U-200Insulin Degludec14$19,777
Breo ElliptaFluticasone/Vilanterol16$15,387
Repatha SyringeEvolocumab11$14,209
LinzessLinaclotide12$13,757
Losartan Potassium861$7,842
Atorvastatin Calcium768$6,699

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,109$220,496188 claims
Lilly USA, LLCTrulicity, Mounjaro$739$106,45773 claims
Boehringer IngelheimJardiance$471$80,23064 claims
GSKTrelegy Ellipta, Breo Ellipta$680$47,85146 claims
Novo NordiskOzempic$1,413$34,23536 claims
Johnson & JohnsonXarelto$198$25,20017 claims
MerckJanuvia$65$22,45615 claims
Astellas Pharma US IncMyrbetriq$513$21,13927 claims
AbbVieLinzess, Synthroid$1,221$19,784174 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Fairlawn

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →